Kailera Therapeutics surges 62.5% in Nasdaq debut after $625 million IPO

Investors rushed into Kailera Therapeutics on its first day of Nasdaq trading, sending the biotech’s shares up 62.5% to an opening price of $26 after the company sold 39.0625 million shares at $16 apiece in a $625 million IPO. The response underscored how aggressively Wall Street is chasing exposure to obesity and GLP-1 therapies, a market many analysts expect could eventually become a $150 billion annual opportunity.

Kailera’s debut immediately placed it among the most closely watched new life-science listings in years. The offering was described as the largest U.S. biotech IPO since Moderna’s $600 million deal in December 2018, a sign that investor appetite has returned for companies with credible shots at the weight-loss trade. That enthusiasm has been reinforced by strategic dealmaking, as buyers and public investors alike have shown a willingness to pay up for programs that could challenge Eli Lilly and Novo Nordisk.

The company’s lead asset is ribupatide, also known as KAI-9531, a once-weekly injectable GLP-1/GIP dual agonist now in global phase 3 trials. Kailera is also advancing KAI-7535, a once-daily small-molecule GLP-1 receptor agonist, along with KAI-9531-T, an oral version of ribupatide, and KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist. Even so, the biggest clinical readouts for the lead program are not expected until 2028, leaving the stock heavily dependent on sentiment in the obesity-drug sector and on the broader biotech market.

Kailera’s pipeline and its financing history explain why investors were willing to move so quickly. The company launched in October 2024 with a $400 million Series A and followed with a $600 million Series B in October 2025 led by Bain Capital Private Equity. It also said it secured exclusive rights in May 2024 to four metabolic-disease assets outside Greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd., giving the company a China-linked origin story that has helped set it apart from other obesity hopefuls.

Ron Renaud, Kailera’s president and chief executive, brings a track record that includes leadership roles at Cerevel Therapeutics and Translate Bio, along with time as a partner at Bain Capital Life Sciences. That pedigree, together with the size of the IPO and the early trading pop, has made Kailera a test case for whether public investors are buying science with long-dated potential or simply chasing the next obesity-market trade. The debut suggests the answer is both, and that capital remains eager to pay for a slice of the GLP-1 boom.